Foros de Conocimiento
medtronic PRODUCTOS
boston_scientific PRODUCTOS
TERUMO PRODUCTOS
Biotronik PRODUCTOS
Sirtex PRODUCTOS
Striker Neurovascular PRODUCTOS
BIOSENSORS PRODUCTOS

NOTICIAS


09 octubre 2012

New Visions PV .035 Digital IVUS Catheter gets FDA clearance and CE mark approval

Interventional NEWS

Volcano has announced it has received FDA clearance and the CE mark to market its new Visions PV .035 Digital IVUS Catheter in both the USA and Europe. The new intravascular ultrasound catheter is designed to image large vessels and facilitate the use of less iodinated contrast in endovascular procedures.

09 octubre 2012

Health Economics of Peripheral Drug-Eluting Balloons Studied

Endovascular Today

October 9, 2012—Many options exist to treat patients with intermittent claudication due to peripheral artery disease of the femoral and/or popliteal vessel(s). Michael R. Jaff, DO, presented a study on the health economics of peripheral drug-eluting balloons and other therapies during a Late-Breaking Trials session at the VIVA 2012: Vascular InterVentional Advances meeting in Las Vegas.

10 octubre 2012

Final Results Presented for Covidien s PFAST-CTOs Study

Endovascular Today

October 10, 2012—The PFAST-CTOs (Peripheral Facilitated Antegrade Steering Technique in Chronic Total Occlusions) trial was a prospective, multicenter, single-arm study intended to demonstrate the ability of the Viance crossing catheter (Covidien, Mansfield, MA) and Enteer reentry system (Covidien) to facilitate safe and effective intraluminal placement of a guidewire beyond challenging peripheral chronic total occlusions (CTOs) without a significant increase in adverse events as compared to the literature. William A. Gray, MD, presented the final results of PFAST-CTO at VIVA 2012: Vascular InterVentional Advances in Las Vegas during a Late-Breaking Trials Session.

10 octubre 2012

One-Year Results From the STROLL Trial Presented

Endovascular Today

October 10, 2012—Michael R. Jaff, DO, presented 1-year results from the STROLL study during a Late-Breaking Trials session at the VIVA 2012: Vascular InterVentional Advances meeting in Las Vegas. STROLL assessed the safety and efficacy of the SMART nitinol self-expandable stent system (Cordis Corporation, Bridgewater, NJ) in treating patients with obstructive superficial femoral artery (SFA) disease. In the United States, the SMART stent is not approved for use in the SFA, and a premarket approval application is currently under review with the US Food and Drug Administration.

03 octubre 2012

UK s NICE consults on new draft quality standard for management of venous thromboembolic diseases

Vascular NEWS

On 3 October, the UK’ National Institute for Health and Clinical Excellence (NICE) opened a consultation on a new draft quality standard for the management of venous thromboembolic (VTE) diseases. The draft quality standard describes markers of high-quality, cost-effective care that, when delivered collectively, should contribute to improving the effectiveness, safety and experience of care for people with venous thromboembolic diseases.

01 octubre 2012

Is carotid intervention in trials becoming safer?

Vascular NEWS

Early results from ACST-2 suggest that modern carotid artery stenting and carotid endarterectomy have a low serious morbidity and mortality, according to early results of the Asymptomatic Carotid Surgery Trial 2 (ACST-2).

17 septiembre 2012

Covidien launches Viance Crossing Catheter and Enteer Re-entry System

Interventional NEWS

Covidien announced at CIRSE 2012 (15–19 September, Lisbon, Portugal) the launch of the Viance Crossing Catheter and Enteer Re-entry System for treating chronic total occlusions (CTOs). The devices are now available in the United States, the European Union and other select international markets.

Utilizamos cookies propias para el correcto funcionamiento del sitio web y mejorar nuestros servicios. Pulse el botón Aceptar todas para aceptar su uso. Puede cambiar la configuración u obtener más información en nuestra Política de cookies o pulsando Modificar configuración.